Which is better, ESTA or RPRX?

On the Buffett-Fit framework, Royalty Pharma plc (RPRX) currently grades higher than ESTA — 66/100 (C grade) vs 30/100 (F). That said, "better" depends on which framework you trust — ESTA wins on none; RPRX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ESTA or RPRX?

This page is an educational comparison, not investment advice. Both ESTA and RPRX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ESTA better than RPRX for value investing?

On the Buffett-style value-investing framework, RPRX currently grades higher — 66/100 vs 30/100, a 36-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ESTA and RPRX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ESTA currently scores 30/100 (F grade); RPRX scores 66/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ESTA or RPRX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ESTA and RPRX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ESTA or RPRX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ESTA and RPRX both Healthcare stocks?

Yes — both Establishment Labs Holdings Inc. (ESTA) and Royalty Pharma plc (RPRX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ESTA vs RPRX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Establishment Labs Holdings

Royalty Pharma

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ESTA

Market cap

$2.12B

Sector

Healthcare

RPRX

Royalty Pharma

Market cap

$23.44B

Sector

Healthcare

Overall winner

Royalty Pharma RPRX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ESTA	RPRX	Winner
Warren Buffett	30F	66C	RPRX
Benjamin Graham	59D	84A	RPRX
Philip Fisher	48D	65C	RPRX
Peter Lynch	52C	60C	RPRX
Joel Greenblatt	0F	40D	RPRX
Charlie Munger	41D	68D	RPRX
Terry Smith	45D	58D	RPRX

Side-by-side metrics

Metric	ESTA	RPRX
Market cap	$2.12B	$23.44B
P/E (TTM)	-	27.6x
EV/EBIT	-	19.9x
ROIC (TTM)	-8.67%	8.43%
Gross margin	70.06%	99.95%
Net margin	-19.05%	33.91%
Revenue CAGR 5y	13.61%	0.96%
EPS CAGR 5y	-	11.83%
Debt / Equity	17.9x	1.3x
Dividend yield	0.0%	1.72%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ESTA leads on

P/E (TTM)-vs 27.6x+162%
EV/EBIT-vs 19.9x+137%
Revenue CAGR 5y13.61%vs 0.96%+93%

RPRX leads on

ROIC (TTM)8.43%vs -8.67%+197%
Net margin33.91%vs -19.05%+156%
Dividend yield1.72%vs 0.0%+100%
Debt / Equity1.3xvs 17.9x+93%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Establishment Labs Holdings

Royalty Pharma

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like ESTA

More like RPRX

Related on invest-like

Key terms in this analysis